<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594958</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-309</org_study_id>
    <nct_id>NCT00594958</nct_id>
  </id_info>
  <brief_title>Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51</brief_title>
  <official_title>Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean
      Titers for anti-JEV neutralizing antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, multi‐center, double blind phase 3 study. The study
      population consists of male and female healthy subjects, aged at least 18 years.

      624 subjects will be enrolled at approximately 6 sites in study centers in Austria and
      Germany.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT for Anti-JEV Neutralizing Antibody</measure>
    <time_frame>day 56</time_frame>
    <description>Equivalence between batches with regards to GMT (Geometric Mean Titer) was postulated if all three pair-wise 95 % Confidence Intervals for GMT ratios were between 0.5 and 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>study duration</time_frame>
    <description>Safety laboratory parameters, rate of SAEs and medically attended AEs, systemic and local tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCR for Anti-JEC Neutralizing Antibody Titer</measure>
    <time_frame>day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">639</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>IC51 Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC51 Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC51 Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <description>6 mcg, intramuscularly [i.m.], 0.5 mL</description>
    <arm_group_label>IC51 Group A</arm_group_label>
    <arm_group_label>IC51 Group B</arm_group_label>
    <arm_group_label>IC51 Group C</arm_group_label>
    <other_name>Japanese Encephalitis purified inactivated vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male and female subjects aged at least 18 years with written informed consent and
             either no childbearing potential or negative pregnancy test

        Main Exclusion Criteria:

          -  History of immunodeficiency or immunosuppressive therapy, known HIV, drug addiction
             including alcohol dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Eder, Mag.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>December 5, 2013</results_first_submitted>
  <results_first_submitted_qc>December 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2014</results_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IC51 Group A</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="P2">
          <title>IC51 Group B</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="P3">
          <title>IC51 Group C</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and at Least 1 Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population, i.e. subjects who received at least one vaccination</population>
      <group_list>
        <group group_id="B1">
          <title>IC51 Group A</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="B2">
          <title>IC51 Group B</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="B3">
          <title>IC51 Group C</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="211"/>
            <count group_id="B4" value="636"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>numbers based on Safety Population: subjects with at least one vaccination</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="10.8"/>
                    <measurement group_id="B2" value="31.3" spread="11.0"/>
                    <measurement group_id="B3" value="30.7" spread="10.3"/>
                    <measurement group_id="B4" value="31.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>numbers based on Safety Population: subjects with at least one vaccination</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GMT for Anti-JEV Neutralizing Antibody</title>
        <description>Equivalence between batches with regards to GMT (Geometric Mean Titer) was postulated if all three pair-wise 95 % Confidence Intervals for GMT ratios were between 0.5 and 2.</description>
        <time_frame>day 56</time_frame>
        <population>Per Protocol Population (observed values)</population>
        <group_list>
          <group group_id="O1">
            <title>IC51 Group A</title>
            <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
          </group>
          <group group_id="O2">
            <title>IC51 Group B</title>
            <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
          </group>
          <group group_id="O3">
            <title>IC51 Group C</title>
            <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
          </group>
        </group_list>
        <measure>
          <title>GMT for Anti-JEV Neutralizing Antibody</title>
          <description>Equivalence between batches with regards to GMT (Geometric Mean Titer) was postulated if all three pair-wise 95 % Confidence Intervals for GMT ratios were between 0.5 and 2.</description>
          <population>Per Protocol Population (observed values)</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.71" lower_limit="140.54" upper_limit="183.76"/>
                    <measurement group_id="O2" value="272.24" lower_limit="237.22" upper_limit="312.43"/>
                    <measurement group_id="O3" value="127.56" lower_limit="109.51" upper_limit="148.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Safety laboratory parameters, rate of SAEs and medically attended AEs, systemic and local tolerability</description>
        <time_frame>study duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCR for Anti-JEC Neutralizing Antibody Titer</title>
        <time_frame>day 56</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Month 6</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IC51 Group A</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="E2">
          <title>IC51 Group B</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
        <group group_id="E3">
          <title>IC51 Group C</title>
          <description>IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Reflux Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Influenza Like Ilness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Intercell AG</organization>
      <phone>+43 1 206 20 ext 0</phone>
      <email>kdubischar-kastner@intercell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

